Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Syncytial Virus (RSV) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

NCT03750383
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Cyclosporine, Prednisone
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

NCT05096208
View directory record Official record
Conditions
RSV
Interventions
RSVpreF (Group 1), RSVpreF (Group 2), RSVpreF (Group 3), Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,028 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
18
States / cities
Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 8, 2026, 10:14 AM EDT
Active, not recruiting No phase listed Observational

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

NCT07249320
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
ABRYSVO
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 50 Years
Enrollment
1 participant
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 8, 2026, 10:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate MEDI-534 in Healthy Adults

NCT00111878
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Parainfluenza Infections
Interventions
MEDI-534
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
3
States / cities
Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2007 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

NCT00121108
View directory record Official record
Conditions
Healthy
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 6 Months
Enrollment
2,127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
12
States / cities
Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

NCT06917508
View directory record Official record
Conditions
RSV Infection, Drug Drug Interaction
Interventions
EDP-323, Midazolam, Caffeine, Rosuvastatin
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation

NCT00016081
View directory record Official record
Conditions
Infection
Interventions
ribavirin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

NCT02254408
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Presatovir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 8, 2026, 10:14 AM EDT
Terminated No phase listed Observational

Emission Patterns of Respiratory Syncytial Virus

NCT03909867
View directory record Official record
Conditions
RSV Infection, Aerosol Disease
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT03596801
View directory record Official record
Conditions
RSV Infection
Interventions
RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 59 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557

NCT00578682
View directory record Official record
Conditions
Healthy
Interventions
MEDI-557
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT03979313
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
3,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
66
States / cities
Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness

NCT00632463
View directory record Official record
Conditions
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
Interventions
RI-001
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
2 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02040831
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 8, 2026, 10:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Early Phase 1 Interventional

A Study of Acute Respiratory Infections in Global Outpatient Setting

NCT05148780
View directory record Official record
Conditions
Acute Respiratory Infection
Interventions
Nasal Swab Sample
Diagnostic Test
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Guntersville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 8, 2026, 10:14 AM EDT
Not yet recruiting Phase 4 Interventional

The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

NCT07824167
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab
Biological
Lead sponsor
Emory University
Other
Eligibility
Up to 8 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 8, 2026, 10:14 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

NCT04605159
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11,194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

NCT00435994
View directory record Official record
Conditions
Bronchiolitis, Respiratory Syncytial Virus Infections
Interventions
Inhaled primatene will be given as a breathing treatment, Nasal Washing
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 2 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers

NCT01355016
View directory record Official record
Conditions
Drug Safety, Respiratory Syncytial Virus Infections
Interventions
MDT-637
Drug
Lead sponsor
MicroDose Therapeutx, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2012 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

NCT02360475
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV vaccine GSK3003895A (formulation 1), RSV vaccine GSK3003898A (formulation 2), RSV vaccine GSK3003899A (formulation 3), Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Mesa, Arizona • San Diego, California • Lenexa, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 8, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

NCT04498741
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 8, 2026, 10:14 AM EDT